Drug monitoring and toxicology: a procedure for the monitoring of levetiracetam and zonisamide by HPLC-UV.
This article describes a rapid isocratic high-performance liquid chromatographic (HPLC) method for the simultaneous measurement of the anticonvulsants levetiracetam and zonisamide. Monitoring these drugs is important for detecting potentially toxic concentrations, particularly in patients with renal impairment, but no commercial assays are currently available. Following a liquid-liquid extraction, levetiracetam (5-150 microg/mL) and zonisamide (5-80 microg/mL) are quantitated by HPLC-UV. The assay's limit of quantitation, linearity, imprecision, and accuracy adequately cover the therapeutic range of these drugs. The assay should be attractive to clinical laboratories because the run time for quantification of both drugs is approximately 5 min per sample, and no interferences are currently known.
Juenke
JoEtta
J
ARUP Institute for Clinical and Experimental Pathology, ARUP Laboratories, Inc., 500 Chipeta Way, Salt Lake City, UT 84108, USA. juenkejm@aruplab.com
Brown
Paul I
PI
Urry
Francis M
FM
McMillin
Gwendolyn A
GA
D000927:Anticonvulsants / Q000097:blood*; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D016903:Drug Monitoring / Q000379:methods*; D006801:Humans; D007555:Isoxazoles / Q000097:blood*; D000077287:Levetiracetam; D010889:Piracetam / Q000031:analogs & derivatives* / Q000097:blood; D015203:Reproducibility of Results; D013056:Spectrophotometry, Ultraviolet / Q000379:methods*; D000078305:Zonisamide
D000927:Anticonvulsants; D007555:Isoxazoles; D000077287:Levetiracetam; D000078305:Zonisamide; D010889:Piracetam